Microneedle Patches for Peptide Delivery
Transdermal Peptide Delivery
< 1 mm Needle Length
Microneedles are 50 to 900 micrometers long, penetrating the stratum corneum without reaching pain-sensing nerve fibers. A 2024 wearable osmotic patch delivered peptides continuously for over a week in animals.
Zhao et al., Nature Biomedical Engineering, 2024
Zhao et al., Nature Biomedical Engineering, 2024
View as imagePeptide drugs have a delivery problem. Most peptides are destroyed by stomach acid and digestive enzymes when taken orally, and the stratum corneum (the outermost dead cell layer of skin) blocks molecules larger than approximately 500 daltons from crossing into the body transdermally. Since most therapeutic peptides range from 1,000 to 10,000 daltons, conventional oral and topical delivery is ineffective for nearly all of them. The result is that peptide therapeutics, from insulin to GLP-1 receptor agonists to growth hormone releasing peptides, require injection. Injection causes pain, requires training, generates sharps waste, and reduces patient adherence, particularly for chronic conditions requiring daily or weekly dosing.
Microneedle patches offer a solution by creating micropores in the stratum corneum through arrays of tiny needles, typically 50 to 900 micrometers in length, that are long enough to bypass the dead cell barrier but too short to reach the pain-sensing nerve fibers and blood vessels in the deeper dermis.[1] The technology has advanced from a concept to active clinical trials, with an abaloparatide microneedle patch completing Phase 1b in 2021 and GLP-1 receptor agonist patches in preclinical development. For a comparison with other non-injection delivery approaches, see Iontophoresis: Using Electricity to Push Peptides Through Skin. For how conventional topical formulations handle the skin barrier, see Topical Peptide Formulations: How Cosmetic and Therapeutic Peptides Penetrate Skin.
Key Takeaways
- An abaloparatide solid microstructured transdermal system (abaloparatide-sMTS) completed a Phase 1b clinical trial, demonstrating bioequivalence to subcutaneous injection with painless self-administration by patients with osteoporosis (Miller et al., Journal of Bone and Mineral Research, 2021)
- A 2024 wearable osmotic microneedle patch achieved sustained peptide delivery for over one week in animal models, using osmotic pressure to continuously drive drug release (Zhao et al., Nature Biomedical Engineering, 2024)
- Liraglutide microneedle patches with pure drug tips achieved pharmacokinetic profiles comparable to subcutaneous injection in both rats and minipigs (Lin et al., Drug Delivery and Translational Research, 2025)
- Transdermal semaglutide delivered via microneedles reduced body weight in mice by suppressing appetite and modulating gut microbiota composition (Li et al., International Journal of Pharmaceutics, 2025)
- A single-administration self-boosting microneedle patch released an anti-obesity peptide in two programmed pulses from one application, eliminating the need for repeated dosing (Singh et al., Advanced Materials, 2024)
- Cell-penetrating peptides enhance transdermal delivery by actively translocating cargo across cell membranes, with mechanisms including direct penetration, endocytosis, and pore formation (Shin et al., Pharmaceutics, 2024)
The skin barrier problem for peptides
The stratum corneum is 10 to 20 micrometers thick and composed of approximately 15 layers of dead, flattened keratinocytes (corneocytes) embedded in a lipid matrix of ceramides, cholesterol, and free fatty acids. This "brick and mortar" structure evolved to prevent water loss and block foreign molecules from entering the body. For small, lipophilic molecules under 500 daltons (like nicotine or fentanyl), conventional transdermal patches can deliver drugs through this barrier by passive diffusion. For peptides, which are hydrophilic, charged, and typically 1,000 to 50,000 daltons, the stratum corneum is effectively impenetrable.
This is why peptide drugs require injection. Insulin (5,808 Da), semaglutide (4,114 Da), liraglutide (3,751 Da), octreotide (1,019 Da), and virtually every other therapeutic peptide is administered by subcutaneous or intramuscular injection. The global peptide therapeutics market exceeds $50 billion annually, and a substantial portion of that market is constrained by the injection requirement. Patients skip doses, delay treatment initiation, and report injection-related anxiety as barriers to adherence, particularly for chronic conditions like diabetes and osteoporosis that require long-term therapy. For the specific challenges of injection site reactions with peptide therapy, the pain and inflammation at injection sites are additional drivers of non-compliance.
Five types of microneedle technology
Microneedle systems are classified into five categories based on how they interact with the skin and deliver their payload.[1]
Solid microneedles
Solid microneedles are applied to the skin and then removed, leaving an array of micropores through which a drug-loaded topical formulation can diffuse. The microneedles create the channels; the drug is applied separately afterward. This approach is simple but requires two steps and relies on passive diffusion through the channels, which close within hours as the skin heals.
Coated microneedles
Microneedles are coated with a dried drug formulation on their surface. Upon insertion into the skin, the coating dissolves in the interstitial fluid of the epidermis/dermis. Drug loading is limited by the small surface area of each needle, making this approach best suited for potent drugs where microgram quantities are sufficient. Vaccine delivery is a natural application.
Dissolving microneedles
The needles themselves are fabricated from a biocompatible, water-soluble polymer (such as hyaluronic acid, polyvinyl alcohol, or sugar) with the drug encapsulated within the needle matrix. Upon insertion, the entire needle dissolves in the skin over minutes to hours, releasing its payload. No sharp waste remains. This is the most actively developed category for peptide delivery because it eliminates sharps disposal and can achieve higher drug loading than coated needles.
The polymer matrix must balance several competing requirements. It needs mechanical strength to penetrate the stratum corneum (which requires a certain rigidity and sharpness), water solubility to dissolve after insertion, and chemical compatibility with the encapsulated peptide to avoid degradation during fabrication and storage. Hyaluronic acid has emerged as a favored matrix material because it is naturally present in skin, fully biocompatible, dissolves rapidly in interstitial fluid, and can be processed at temperatures that preserve peptide bioactivity. The concentration of hyaluronic acid, the molecular weight selected, and the drying conditions during needle fabrication all affect the dissolution rate and peptide release kinetics.
Hollow microneedles
Miniaturized versions of conventional hypodermic needles, hollow microneedles have a bore through which liquid drug formulations flow into the skin. They can deliver larger volumes than solid or dissolving types but are mechanically more complex and fragile.
Hydrogel microneedles
Made from cross-linked hydrogel polymers, these needles swell upon insertion as they absorb interstitial fluid, creating channels through which drugs diffuse from a reservoir backing. The swelling can be engineered to control release rate.
Clinical milestone: abaloparatide microneedle patch
The most advanced clinical data for microneedle peptide delivery comes from abaloparatide, a parathyroid hormone-related peptide analog used to treat osteoporosis. Miller et al. (2021) reported Phase 1b results for abaloparatide-sMTS (solid microstructured transdermal system), a microneedle patch designed to replace daily subcutaneous injection.[2]
The patch achieved bioequivalence to subcutaneous injection, meaning it delivered comparable plasma drug concentrations over comparable timeframes. Patients self-administered the patches at home with minimal training. Pain scores were markedly lower than subcutaneous injection. The Phase 1b demonstrated that microneedle technology can deliver a therapeutic peptide at clinically relevant doses through the skin with a pharmacokinetic profile suitable for the intended indication.
This is a meaningful proof of concept because abaloparatide (3,960 Da) is similar in size to many peptide drugs: it falls in the same molecular weight range as GLP-1 receptor agonists, growth hormone releasing peptides, and antimicrobial peptides. If microneedle delivery works for abaloparatide, the platform is potentially adaptable to dozens of other peptide therapeutics.
GLP-1 receptor agonists: the major target
The largest commercial opportunity for microneedle peptide delivery is the GLP-1 receptor agonist class, which includes semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda). These drugs dominate the diabetes and obesity markets but require weekly (semaglutide) or daily (liraglutide) injection.
Lin et al. (2025) developed microneedle patches with pure drug tips for liraglutide delivery. By concentrating the drug in the needle tips rather than distributing it throughout the backing material, they overcame the loading capacity limitation of conventional dissolving microneedles. Pharmacokinetic studies in rats and minipigs showed comparable absorption profiles to subcutaneous injection.[3]
Li et al. (2025) demonstrated transdermal semaglutide delivery via microneedles in mice. The transdermally delivered semaglutide reduced body weight by suppressing appetite and, unexpectedly, modulated gut microbiota composition, suggesting that the route of delivery may influence the drug's biological effects beyond simple pharmacokinetic equivalence.[4]
Jia et al. (2025) developed silk fibroin hollow microneedles for sustained liraglutide administration. Silk fibroin's natural biocompatibility and tunable degradation rate allowed controlled release over an extended period, potentially reducing dosing frequency from daily to every few days.[5]
Chen et al. (2025) focused on enhanced transdermal delivery of liraglutide for sustained obesity management, using formulation strategies to improve the stability and absorption of the peptide through microneedle-created channels.[6]
These are all preclinical studies. No GLP-1 microneedle patch has entered human clinical trials. The challenge is scaling from animal models (where small patches can deliver sufficient drug relative to body weight) to human-sized patches that can deliver the milligram quantities required for therapeutic effect.
The commercial incentive is substantial. Semaglutide (Ozempic/Wegovy) generated over $20 billion in annual revenue by 2025, with supply shortages driven partly by injection device manufacturing capacity. A transdermal patch that eliminated the injection pen and its associated manufacturing complexity could address both patient preference and supply chain constraints. The weekly dosing schedule of semaglutide is well-suited to microneedle delivery: a once-weekly patch application is a natural fit for dissolving or sustained-release microneedle systems that deliver their payload over hours to days.
For liraglutide, which requires daily injection, the advantage is even more pronounced. Daily injections create substantial adherence challenges, and patients frequently cite injection burden as a reason for discontinuing GLP-1 therapy. A daily patch that patients apply to the skin and forget, with no needle disposal required, could improve real-world adherence beyond what clinical trial completion rates suggest.
Advanced microneedle designs
Wearable sustained-release patches
Zhao et al. (2024) published a study in Nature Biomedical Engineering describing a wearable osmotic microneedle patch that provided sustained peptide delivery for over one week in animal models. The patch used osmotic pressure gradients to continuously drive drug release from a reservoir through the microneedle channels, maintaining therapeutic drug levels without patch replacement.[7] This represents a shift from single-application patches (which deliver their payload in minutes to hours) to wearable systems that function as continuous delivery devices.
Self-boosting single-application patches
Singh et al. (2024) designed a single-administration microneedle patch that released an anti-obesity peptide in two programmed pulses from one application. The first pulse delivered an immediate dose upon insertion; the second pulse released additional drug from a degradable polymer compartment days later. This "self-boosting" design mimics the pharmacokinetics of repeated injections from a single patch application.[8]
Double-layered systems
Xu et al. (2025) developed a novel double-layered system combining PLGA microparticles with dissolving microneedles. The PLGA microparticles provide sustained release of encapsulated peptide drug after the dissolving microneedle deposits them into the dermis. This approach addresses both the skin barrier problem (via the dissolving microneedle) and the sustained release problem (via the slow-degrading PLGA particles) in a single device.[9]
Beyond drug delivery: vaccines and diagnostics
Microneedle patches have applications in peptide-based vaccines and skin diagnostics that extend the technology beyond therapeutic drug delivery.
Meneveau et al. (2021) reported immunogenicity data in humans from a transdermal multipeptide melanoma vaccine delivered via microneedle patch. The skin is rich in antigen-presenting cells (Langerhans cells and dermal dendritic cells), making intradermal delivery potentially more immunogenic than intramuscular injection for peptide vaccines.[10]
Su et al. (2024) demonstrated microneedle co-delivery of monoclonal antibodies and engineered peptide fragments for cancer immunotherapy, showing that the platform can handle both large proteins and smaller peptides simultaneously.[11] The vaccine application is particularly compelling because intradermal delivery requires much lower antigen doses than intramuscular injection (often 10-20% of the standard dose), the skin's immune surveillance cells provide natural adjuvant effects, and microneedle patches could be stored and transported without cold chain requirements if the peptide antigens are stabilized in the dried needle matrix. For pandemic preparedness, self-administered microneedle vaccine patches that do not require healthcare workers, needles, or refrigeration represent a transformative potential.
Cell-penetrating peptides as delivery enhancers
An alternative approach to microneedle-based physical barrier disruption is using cell-penetrating peptides (CPPs) to carry cargo across the skin. Shin et al. (2024) reviewed the transdermal properties of CPPs, which are short peptide sequences (typically 5 to 30 amino acids) that can translocate across cell membranes through direct penetration, endocytosis, or transient pore formation.[12]
CPPs can be conjugated to therapeutic peptides or co-formulated with them to enhance skin penetration. However, CPP-mediated delivery is limited to relatively small payloads and achieves lower bioavailability than microneedle-based approaches. The two technologies are complementary: microneedles create physical channels through the stratum corneum, while CPPs enhance cellular uptake of the drug once it reaches viable skin layers. A combined approach, using dissolving microneedles loaded with CPP-conjugated peptides, could maximize delivery efficiency.
The best-characterized CPPs for transdermal use include TAT peptide (derived from HIV transactivator of transcription), penetratin (from the Drosophila Antennapedia homeodomain), and polyarginine sequences. Each uses different mechanisms to cross cell membranes: TAT enters through macropinocytosis, penetratin through direct membrane translocation, and polyarginine through electrostatic interaction with negatively charged membrane components. The choice of CPP affects the size of cargo that can be delivered, the kinetics of cellular uptake, and the intracellular fate of the delivered peptide.
Li et al. (2015) provided an early demonstration of this concept by using microneedles to deliver the copper peptide GHK-Cu through skin. The study showed that microneedle pretreatment increased GHK-Cu permeation by orders of magnitude compared to passive topical application.[13] For more on GHK-Cu itself, see GHK-Cu: The Copper Peptide That Modulates Over 4,000 Genes. For how lipid-based carriers compare as peptide delivery vehicles, see Liposomal Peptide Delivery: Wrapping Peptides in Fat Bubbles.
What stands between microneedles and clinical use
The science is advancing rapidly, but several barriers separate preclinical promise from clinical reality. Drug loading capacity remains the primary limitation: dissolving microneedle patches can typically deliver micrograms to low milligrams of peptide, while many therapeutic peptides require milligram-range doses. Scaling patch size or needle density to increase loading introduces manufacturing challenges and may compromise skin tolerability.
Stability of peptides within microneedle matrices is another concern. Peptides can aggregate, degrade, or lose bioactivity during the fabrication process (which may involve heat, solvents, or drying) or during storage. Each peptide-microneedle combination requires its own stability optimization.
Regulatory pathways for microneedle drug-device combinations are still evolving. The product is simultaneously a drug (the peptide) and a device (the microneedle patch), requiring dual regulatory consideration through either the drug or device review pathway, or a combination product pathway that involves both FDA centers. Sterility assurance for a product that creates skin punctures adds another layer of manufacturing and testing requirements. The abaloparatide-sMTS Phase 1b represents the most advanced regulatory engagement for a peptide microneedle product and will likely set precedent for how subsequent microneedle peptide products are reviewed.
Dashti et al. (2025) demonstrated the breadth of potential applications by developing polylactic acid microneedles for desmopressin, a peptide used to treat diabetes insipidus and nocturnal enuresis, showing that the technology is being explored across diverse peptide drug classes.[14]
Manufacturing scale-up is a separate challenge from the science. Microneedle patches require precise, reproducible fabrication of needle arrays with consistent dimensions, drug loading, and mechanical properties across millions of units. Current academic fabrication methods (soft lithography, micro-molding, 3D printing) work at laboratory scale but have not been validated for commercial-scale production meeting pharmaceutical good manufacturing practice (GMP) standards. The cost per patch must also be competitive with existing injection devices, which have benefited from decades of manufacturing optimization.
The patient experience advantage may ultimately drive adoption even if early microneedle products are not perfectly optimized. A patch that delivers 80% of the drug with zero pain may be preferable to an injection that delivers 100% with discomfort and inconvenience. For chronic conditions requiring years of treatment, patient preference and adherence are not minor factors but primary determinants of real-world treatment effectiveness.
The Bottom Line
Microneedle patches bypass the skin's stratum corneum barrier to deliver peptide drugs painlessly, without generating sharps waste. The technology spans five categories (solid, coated, dissolving, hollow, and hydrogel), each with different loading capacities, release kinetics, and manufacturing requirements. An abaloparatide microneedle patch has completed Phase 1b clinical testing with bioequivalence to injection. Multiple groups are developing microneedle patches for GLP-1 receptor agonists (liraglutide, semaglutide), with promising preclinical pharmacokinetics. Advanced designs include wearable osmotic patches for week-long delivery and self-boosting patches for pulsatile release. The primary remaining challenges are drug loading capacity, peptide stability during manufacturing, and regulatory pathway development.